262 related articles for article (PubMed ID: 12926149)
1. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study.
Rosati G; Rossi A; Germano D; Reggiardo G; Manzione L
Anticancer Res; 2003; 23(3C):2981-5. PubMed ID: 12926149
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
4. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
6. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
[TBL] [Abstract][Full Text] [Related]
7. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
[TBL] [Abstract][Full Text] [Related]
9. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Tsavaris N; Kosmas C; Vadiaka M; Koufos C
BMC Cancer; 2002; 2():2. PubMed ID: 11860608
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Aparicio J; Vicent JM; Maestu I; Garcerá S; Busquier I; Bosch C; Llorca C; Díaz R; Fernández-Martos C; Galán A
Ann Oncol; 2003 Jul; 14(7):1121-5. PubMed ID: 12853356
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
15. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
Cascinu S; Graziano F; Ferraù F; Catalano V; Massacesi C; Santini D; Silva RR; Barni S; Zaniboni A; Battelli N; Siena S; Giordani P; Mari D; Baldelli AM; Antognoli S; Maisano R; Priolo D; Pessi MA; Tonini G; Rota S; Labianca R
Ann Oncol; 2002 May; 13(5):716-20. PubMed ID: 12075739
[TBL] [Abstract][Full Text] [Related]
16. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
[TBL] [Abstract][Full Text] [Related]
18. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Kouroussis C; Souglakos J; Mavroudis D; Papadouris S; Kakolyris S; Agelaki S; Kalbakis K; Panopoulos C; Vardakis N; Sarra E; Georgoulias V
Am J Clin Oncol; 2002 Dec; 25(6):627-31. PubMed ID: 12478014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
